Safety Implications of Vascular Endothelial Growth Factor Blockade for Subjects Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Therapies

American Journal of Ophthalmology

Volumn 148, Issue 5, 2009, Pages 647-656

  Csaky, Karl ^a   Do, Diana V ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; AGENTS ACTING ON THE EYE; BEVACIZUMAB; BEVASIRANIB; PAZOPANIB; PEGAPTANIB; RANIBIZUMAB; ROFECOXIB; SIRNA 027; TG 100801; TIMOLOL MALEATE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR; VATALANIB; VERTEPORFIN;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTERY THROMBOSIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; DIABETIC MACULAR EDEMA; DISEASE REGISTRY; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERANCE; ELECTRONIC MEDICAL RECORD; ENDOPHTHALMITIS; EYE INFLAMMATION; GLAUCOMA; HEART INFARCTION; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE; LUNG CANCER; LUNG DISEASE; MEDICAL LITERATURE; MEDICAL RECORD REVIEW; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; SIDE EFFECT; STROKE; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC CIRCULATION; TRAUMATIC CATARACT; UNSPECIFIED SIDE EFFECT; UVEITIS; VITREOUS HEMORRHAGE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; DATABASES, FACTUAL; DRUG ADMINISTRATION ROUTES; HUMANS; MACULAR DEGENERATION; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; META-ANALYSIS AS TOPIC; PRODUCT SURVEILLANCE, POSTMARKETING; RECOMBINANT FUSION PROTEINS; REGISTRIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70350575734     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2009.06.014     Document Type: Article

References (47)

1. Friedman D.S., O'Colmain B.J., Munoz B., et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122 (2004) 564-572
2. Bressler S., and Rosberger D. Non-neovascular (non-exudative) age-related macular degeneration. In: Guyer D., Yannuzzi L., Chang S., Shields J., and Green W.R. (Eds). Retina-Vitreous-Macula (1999), W. B. Saunders Co, Philadelphia, Pennsylvania 79-93
3. Kleinman M.E., Yamada K., Takeda A., et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452 (2008) 591-597
4. Saint-Geniez M., Maharaj A.S., Walshe T.E., et al. Endogenous VEGF is required for visual function: evidence for a survival role on Muller cells and photoreceptors. PLoS ONE 3 (2008) e3554
5. Cunha-Vaz J.G. The blood-ocular barriers: past, present, and future. Doc Ophthalmol 93 (1997) 149-157
6. Shell J.W. Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol 26 (1982) 207-218
7. Labetoulle M., Frau E., and Le Jeunne C. Systemic adverse effects of topical ocular treatments. Presse Med 34 (2005) 589-595
8. Le Jeunne C., Hugues F.C., Munera Y., and Haas C. [Systemic effects of eye drops]. Ann Med Interne (Paris) 141 (1990) 674-677
9. Botet C., Grau J., Benito P., Coll J., and Vivancos J. Timolol ophthalmic solution and respiratory arrest. Ann Intern Med 105 (1986) 306-307
10. Van Buskirk E.M. Adverse reactions from timolol administration. Ophthalmology 87 (1980) 447-450
11. Stewart W.C., and Garrison P.M. Beta-blocker-induced complications and the patient with glaucoma. Newer treatments to help reduce systemic adverse events. Arch Intern Med 158 (1998) 221-226
12. Los M., Roodhart J.M., and Voest E.E. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12 (2007) 443-450
13. Kabbinavar F.F., Hambleton J., Mass R.D., Hurwitz H.I., Bergsland E., and Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23 (2005) 3706-3712
14. Scappaticci F.A., Skillings J.R., Holden S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99 (2007) 1232-1239
15. Longo R., and Gasparini G. Challenges for patient selection with VEGF inhibitors. Cancer Chemother Pharmacol 60 (2007) 151-170
16. Chakravarthy U., Adamis A.P., Cunningham Jr. E.T., et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 1508-1525
17. Rosenfeld P.J., Brown D.M., Heier J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
18. Brown D.M., Michels M., Kaiser P.K., Heier J.S., Sy J.P., and Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study. Ophthalmology 116 (2009) 57-65
19. Alexander S.L., Linde-Zwirble W., Werther W., et al. Annual rates of arterial thromboembolic events in Medicare neovascular age-related macular degeneration patients. Ophthalmology 114 (2007) 2174-2178
20. Bakri S.J., Snyder M.R., Reid J.M., Pulido J.S., Ezzat M.K., and Singh R.J. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114 (2007) 2179-2182
21. Gaudreault J., Fei D., Beyer J.C., et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 27 (2007) 1260-1266
22. Bakri S.J., Snyder M.R., Reid J.M., Pulido J.S., and Singh R.J. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114 (2007) 855-859
23. Moshfeghi A.A., Rosenfeld P.J., Puliafito C.A., et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: 24-week results of an uncontrolled open-label clinical study. Ophthalmology 113 (2006) e1-e12
24. Avery R.L., Pieramici D.J., Rabena M.D., Castellarin A.A., Nasir M.A., and Giust M.J. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 363-372.e5
25. Spaide R.F., Laud K., Fine H.F., et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26 (2006) 383-390
26. Wong L.J., Desai R.U., Jain A., et al. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Retina 28 (2008) 1151-1158
27. Bashshur Z.F., Haddad Z.A., Schakal A., Jaafar R.F., Saab M., and Noureddin B.N. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 145 (2008) 249-256
28. Fung A.E., Rosenfeld P.J., and Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90 (2006) 1344-1349
29. Konner J., and Dupont J. Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF trap) to inhibit vascular endothelial growth factor activity. Clin Colorectal Cancer 4 (2004) S81-S85
30. Stewart M.W., and Rosenfeld P.J. Predicted biological activity of intravitreal VEGF trap. Br J Ophthalmol 92 (2008) 667-668
31. Economides A.N., Carpenter L.R., Rudge J.S., et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 9 (2003) 47-52
32. Kaiser P.K. Anti-vascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol 142 (2006) 660-668
33. Nguyen Q.D., Shah S.M., Hafiz G., et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113 (2006) 1522e1-1522e14
34. Berlin J.A., Glasser S.C., and Ellenberg S.S. Adverse event detection in drug development: recommendations and obligations beyond phase 3. Am J Public Health 98 (2008) 1366-1371
35. Mukherjee D., Nissen S.E., and Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286 (2001) 954-959
36. Jones D. Keeping vigilant about drug safety. Nat Rev Drug Discov 6 (2007) 855-856
37. Wilson A.M., Thabane L., and Holbrook A. Application of data mining techniques in pharmacovigilance. Br J Clin Pharmacol 57 (2004) 127-134
38. Honigman B., Lee J., Rothschild J., et al. Using computerized data to identify adverse drug events in outpatients. J Am Med Inform Assoc 8 (2001) 254-266
39. Meyboom R.H., Egberts A.C., Edwards I.R., Hekster Y.A., de Koning F.H., and Gribnau F.W. Principles of signal detection in pharmacovigilance. Drug Saf 16 (1997) 355-365
40. Ahmad S.R. Adverse drug event monitoring at the Food and Drug Administration. J Gen Intern Med 18 (2003) 57-60
41. Scott H.D., Rosenbaum S.E., Waters W.J., et al. Rhode Island physicians' recognition and reporting of adverse drug reactions. R I Med J 70 (1987) 311-316
42. Rogers A.S., Israel E., Smith C.R., et al. Physician knowledge, attitudes, and behavior related to reporting adverse drug events. Arch Intern Med 148 (1988) 1596-1600
43. Edwards I.R., Lindquist M., Wiholm B.E., and Napke E. Quality criteria for early signals of possible adverse drug reactions. Lancet 336 (1990) 156-158
44. Ziemssen F., Grisanti S., and Bartz-Schmidt K.U. The international intravitreal bevacizumab safety survey. Br J Ophthalmol 90 (2006) 1440-1441
45. Gaudreault J., Fei D., Rusit J., Suboc P., and Shiu V. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46 (2005) 726-733
46. Drolet D.W., Nelson J., Tucker C.E., et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 17 (2000) 1503-1510
47. Moshfeghi A.A., and Puliafito C.A. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs 14 (2005) 671-682